Form 4: Karyopharm Chief Accounting Officer Sells Shares for Tax

Karyopharm Therapeutics' Chief Accounting Officer, Kristin Abate, sold 12 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Summary

• Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics Inc. (KPTI), reported a sale of common stock.
• The transaction involved the disposition of 12 shares of Karyopharm Therapeutics Inc. common stock.
• The shares were sold at a price of $6.78 per share.
• The sale occurred on September 3, 2025.
• This transaction was not a discretionary trade but was executed pursuant to a durable automatic sale instruction plan adopted on May 27, 2021.
• The purpose of the sale was to satisfy withholding tax liability incurred upon the vesting of restricted stock units.
• Following this transaction, Kristin Abate beneficially owns 9,463 shares of common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary sale of a small number of shares by an executive to cover tax obligations from RSU vesting. This is a neutral event with no significant positive or negative implications for the company's operations or stock performance.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine insider transaction report and does not provide information relevant to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, but it is a non-discretionary tax-related transaction and not indicative of a change in management's confidence in the company.

Key Dates

Keywords

Karyopharm Therapeutics, KPTI, Kristin Abate, Chief Accounting Officer, Insider Trading, Form 4, Stock Sale, Tax Liability, Restricted Stock Units, RSU Vesting